Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/themotleyfool.ico', homepage_url='https://www.fool.com/', logo_url='https://s3.massive.com/public/assets/news/logos/themotleyfool.svg', name='The Motley Fool')•2026-03-04
Why NeuroPace Stock Was Inching Higher on WednesdayNPCE — Neuropace Inc
NASDAQ · Health Care · Health Care
$16.37-2.44%Market cap455.51M
- Latest Close
- $16.37
- 30-Day Move
- -2.4%
- Market Cap
- $456M
- Shares Outstanding
- 33,670,000
- P/B Ratio
- 27.02
- ROE
- -112.8%
Analyst consensus: Buy · 14 analysts
NASDAQ:NPCEHealth Care / Health CareDelayed public snapshot
Neuropace Inc
A read-only Alphactor snapshot forNeuropace Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$16.37
30-Day Move
-2.4%
Market Cap
$456M
Shares Outstanding
33,670,000
P/B Ratio
27.02
ROE
-112.8%
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$16.37
-2.4%last 90 delayed daily bars
Market cap$456M
90D High
$17.90
90D Low
$12.47
Avg Volume
206,196
What stands out
Gross margin is running at 77.2%, which gives a quick read on operating quality before you open the full model.
Net margin is -21.5%, useful for comparing NPCE against peers in Health Care.
NPCE is down 2.4% over the last 30 trading days shown on this page.
Latest operating income is $-2M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Composite Fair Value
$13.39
Rule of 40
13.8%
Dark Pool Short %
40.4%
Fundamentals snapshot
Latest Close
$16.37
30-Day Move
-2.4%
Market Cap
$456M
Shares Outstanding
33,670,000
P/B Ratio
27.02
ROE
-112.8%
ROA
-20.3%
Gross Margin
77.2%
Operating Margin
-16.8%
Net Margin
-21.5%
Debt / Equity
3.09
Current Ratio
5.28
Latest Revenue
$27M
Financial statement snapshot
Revenue
$27M
Gross Profit
$21M
Operating Income
$-2M
Net Income
$-3M
Gross Margin
7723.0%
Net Margin
-2147.0%
Current Ratio
5.28
Debt / Equity
3.09
Valuation snapshot
Fair Value
$13.39
Upside / Downside
-18.2%
Signal
Overvalued
Implied Growth
--
EV/Rev
$13.39
Growth Assumption
30.0%
Discount Rate
11.3%
Terminal Growth
2.0%
Base FCF
--
Valuation spread
Current Price
$16.37
Composite Fair Value
$13.39
EV/Rev
$13.39
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Negative FCF — company is cash-flow negative. Reverse DCF requires positive cash flows.
Quality snapshot
Altman Z
-2.86
Distress
Piotroski
5
Moderate (4-6)
Cash Conversion
0.51x
Rule of 40
13.8%
Concerning
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $46M | $-41M | $-47M | $-37M |
| 2023-12-31 | $65M | $-27M | $-33M | $-20M |
| 2024-12-31 | $80M | $-22M | $-27M | $-18M |
| 2025-12-31 | $100M | $-16M | $-21M | $-11M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2025-05-28
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCEPublisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2025-03-04
UPDATE – NeuroPace to Present at the Leerink Partners Global Healthcare ConferencePublisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2024-11-11
Neuroscience Market Projected to Reach USD 50.2 Billion by 2032, Growing at a 4.0% CAGR – S&S InsiderPublisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/zacks.ico', homepage_url='https://www.zacks.com/', logo_url='https://s3.massive.com/public/assets/news/logos/zacks.png', name='Zacks Investment Research')•2024-05-07
Globus Medical (GMED) Q1 Earnings and Revenues Beat EstimatesAfter signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Insider activity snapshot
Buy Value
$0
Sell Value
$3M
Buys
0
Sells
3
Buy Value
$0
Sell Value
$3M
Buy/Sell Ratio
0.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
Recent insider transactions
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-24 | Morrell Martha | F | 1,341 | $13.27 |
| 2026-03-20 | Geiger Uri | A | 913 | $13.00 |
| 2026-03-20 | LACOB JOSEPH | A | 865 | $13.00 |
| 2026-03-20 | Kumar Rakhi | A | 1,153 | $13.00 |
| 2026-03-20 | Fischer Frank M | A | 1,826 | $13.00 |
| 2026-03-03 | Morrell Martha | F | 1,340 | $13.83 |
| 2026-03-03 | Becker Joel | F | 5,023 | $13.83 |
| 2026-02-27 | Morrell Martha | F | 358 | $14.58 |
Institutional holders snapshot
Vanguard Group
Filed 2026-01-29
$23M
+3.2%
FMR LLC (Fidelity)
Filed 2026-02-17
$10M
+0.1%
Geode Capital Management
Filed 2026-02-09
$9M
+6.5%
BlackRock
Filed 2024-08-13
$5M
--
Northern Trust
Filed 2026-02-17
$4M
-2.0%
Renaissance Technologies
Filed 2026-02-12
$3M
+72.2%
Qube Research & Technologies
Filed 2026-02-17
$3M
-6.9%
Dark-pool activity snapshot
Analyst consensus?
Rating(?)
4.21
Consensus
BuyTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
14
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.